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137 Abstract Pituitary adenylate cyclase-activating polypeptide (PACAP) is a
widespread neuropeptide acting as a neurotransmitter,
neuromodulator, or neurotrophic factor. The diverse biological
actions provide the background for the variety of deficits observed
in mice lacking endogenous PACAP. PACAP-deficient mice
display several abnormalities, such as sudden infant death
syndrome (SIDS)-like phenotype, decreased cell protective
functions, and increased risk of Parkinson’s disease but their
molecular mechanisms and proteomic background are unclear in
majority. Therefore, our aim was to investigate the differences in
peptide and protein composition in the brains of PACAP-deficient
and wild-type mice using sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and mass spectrometric
(MS)-based proteomic analysis. Brains from PACAP-deficient mice
were removed, and different brain areas (cortex, hippocampus,
diencephalon, mesencephalon, brainstem, and cerebellum) were
separated. Brain pieces were weighed, homogenized, and further
processed for electrophoretic analysis. Our results revealed several
differences in diencephalon and mesencephalon. The protein
bands of interest were cut from the gel, samples were digested with
trypsin, and the tryptic peptides were measured by matrix-assisted
laser desorption ionization time of fl ight (MALDI TOF) MS. Results
were analyzed by MASCOT Search Engine. Among the altered
proteins, several are involved in metabolic processes, energy
homeostasis, and structural integrity. ATP-synthase and tubulin
beta-2A were expressed more strongly in PACAP-knockout mice. In
contrast, the expression of more peptides/proteins markedly
decreased in knockout mice, l ike pyruvate kinase, fructose
biphosphate aldolase-A, glutathione S-transferase, peptidyl propyl
cis-trans isomerase-A, gamma enolase, and aspartate amino
transferase. The altered expression of these enzymes might
partially account for the decreased antioxidant and detoxifying
capacity of PACAP-deficient mice accompanying the increased
vulnerabil ity of these animals. Our results provide novel insight into
the altered biochemical processes in mice lacking endogenous
PACAP.
138 Keywords
separated by ' - '
PACAP - Knockout - MALDI - Proteomics
139 Foot note
information
   
   
AUTHOR'S PROOF
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
1
2
3
4 Comparative Protein Composition of the Brains
5 of PACAP-Deficient Mice Using Mass Spectrometry-Based
6 Proteomic Analysis
8 G. Maasz & Z. Pirger & D. Reglodi & D. Petrovics & J. Schmidt & P. Kiss & A. Rivnyak &
9 H. Hashimoto & P. Avar & E. Jambor & A. Tamas & B. Gaszner &
10 L. Mark & MTA-PTE Human Reproduction Research Group &
11 PTE MTA Lendulet PACAP Research Team
12
13
14 Received: 24 December 2013 /Accepted: 13 February 2014
15 # Springer Science+Business Media New York 2014
16 Abstract Pituitary adenylate cyclase-activating polypeptide
17 (PACAP) is a widespread neuropeptide acting as a neurotrans-
18 mitter, neuromodulator, or neurotrophic factor. The diverse
19 biological actions provide the background for the variety of
20 deficits observed in mice lacking endogenous PACAP.
21 PACAP-deficient mice display several abnormalities, such as
22 sudden infant death syndrome (SIDS)-like phenotype, de-
23 creased cell protective functions, and increased risk of
24 Parkinson’s disease but their molecular mechanisms and pro-
25 teomic background are unclear in majority. Therefore, our aim
26 was to investigate the differences in peptide and protein com-
27 position in the brains of PACAP-deficient and wild-type mice
28 using sodium dodecyl sulfate-polyacrylamide gel
29electrophoresis (SDS-PAGE) and mass spectrometric (MS)-
30based proteomic analysis. Brains from PACAP-deficient mice
31were removed, and different brain areas (cortex, hippocampus,
32diencephalon, mesencephalon, brainstem, and cerebellum)
33were separated. Brain pieces were weighed, homogenized,
34and further processed for electrophoretic analysis. Our results
35revealed several differences in diencephalon and mesencepha-
36lon. The protein bands of interest were cut from the gel,
37samples were digested with trypsin, and the tryptic peptides
38were measured by matrix-assisted laser desorption ionization
39time of flight (MALDI TOF) MS. Results were analyzed by
40MASCOT Search Engine. Among the altered proteins, several
41are involved in metabolic processes, energy homeostasis, and
42structural integrity. ATP-synthase and tubulin beta-2A were
43expressed more strongly in PACAP-knockout mice. In con-
44trast, the expression of more peptides/proteins markedly de-
45creased in knockout mice, like pyruvate kinase, fructose
46biphosphate aldolase-A, glutathione S-transferase, peptidyl
47propyl cis-trans isomerase-A, gamma enolase, and aspartate
48amino transferase. The altered expression of these enzymes
49might partially account for the decreased antioxidant and de-
50toxifying capacity of PACAP-deficient mice accompanying
51the increased vulnerability of these animals. Our results pro-
52vide novel insight into the altered biochemical processes in
53mice lacking endogenous PACAP.
54Keywords PACAP . Knockout .MALDI . Proteomics
55Introduction
56Pituitary adenylate cyclase activating polypeptide (PACAP) is
57a hypothalamic neuropeptide that was first isolated from ovine
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58 hypothalamic (Miyata et al. 1989). PACAP occurs in the
59 nervous system and almost all peripheral organs (Vaudry
60 et al. 2009). PACAP has diverse biological effects, including
61 behavioral actions, effects on biological rhythms, reproduc-
62 tion, and cardiovascular and gastrointestinal functions
63 (Vaudry et al. 2009). It is also well-known that PACAP is part
64 of the cellular protective machinery. The neuroprotective ef-
65 fects of both endogenous and exogenous PACAP are inten-
66 sively investigated because PACAP is a promising neuropro-
67 tective peptide. Strong neuroprotective effects have been
68 shown in numerous models of in vitro and in vivo injuries,
69 including retinal and cerebral lesions (Fabian et al. 2012;
70 Atlasz et al. 2007), neurodegenerative diseases (Brown et al.
71 2013), and toxic injuries (Wada et al. 2013). The protective
72 effect of endogenous PACAP is mainly supported by obser-
73 vations in PACAP-deficient mice (Reglodi et al. 2012). The
74 increased susceptibility of PACAP-deficient mice has been
75 described in numerous models. The first descriptions come
76 from cerebellar granule cells exposed to oxidative stress or
77 ethanol. Vaudry and coworkers described that cultured gran-
78 ule cells from PACAP-deficient mice respond with increased
79 cell death to the same injury (Vaudry et al. 2005). Subsequent
80 studies have confirmed these original observations in other
81 cultured cells (Horvath et al. 2010). In vivo, similar findings
82 have been published. Knockout mice exposed to cerebral
83 ischemia have increased brain infarct volume compared to
84 wild-type mice (Reglodi et al. 2012; Ohtaki et al. 2006). For
85 example, mice lacking endogenous PACAP have increased
86 vulnerability to different stressors and toxic insults, and they
87 also have accelerated aging. PACAP-deficient mice show
88 increased infarct size in a stroke model (Ohtaki et al. 2008)
89 and increased sensitivity to neuroinflammation accompanying
90 a model of Parkinson’s disease (Watson et al. 2013) and
91 increased retinal injury in mice exposed to bilateral carotid
92 artery occlusion (Szabadfi et al. 2012). Some biochemical
93 alterations have been described in the background of these
94 findings. However, very little is known about the proteomics
95 of PACAP-deficient mice, and mass spectrometric analysis
96 has not yet been done in these mice. Therefore, our aim was to
97 map the proteomic profile in different brain regions of wild-
98 type and knockout mice focusing on the present differences
99 and quantitatively comparing the proteins found in both types.
100 Materials and Methods
101 Animals
102 The generation and maintenance of the knockout mice on the
103 CD1 background have been previously described in detail
104 (Hashimoto et al. 2001; Hashimoto et al. 2009); they were
105 backcrossed for ten generations with the CD1 strain. Wild-
106 type (PACAP+/+, n=5) and homozygous PACAP-deficient
107mice (PACAP−/−, n=5) were used. Animals were fed and
108watered ad libitum under light/dark cycles of 12/12 h. All
109procedures were performed in accordance with the ethical
110guidelines and under approved protocols (ethical permission
111number: University of Pecs BA02/2000-15024/2011).
112Sample Preparation
113Wild-type and homozygous PACAP-deficient mice were
114sacrificed under isoflurane anesthesia. Brains were removed
115and different brain areas (frontal cortex, temporal lobe–dien-
116cephalon complex, mesencephalon, rest of the brainstem
117(pons and medulla), and cerebellum) were dissected. Two
118hundred microliters of lysis buffer (2 mM EDTA, 10 mM
119EGTA, 20 mM HEPES, pH 7.5) was added to 50 mg brain
120tissue. LoRetention pipette tips (Eppendorf, Wien, Austria)
121and Lobind Eppendorf tubes (Eppendorf) were used during all
122steps of sample preparation to avoid protein loss. The tissue
123was homogenized, and cells were explored for 6×10 s with a
124high energy UIS250V ultrasonicator (Hielsher Ultrasound
125Technology, Teltow, Germany) applying ice cooling between
126the cycles. Samples were vortex mixed and centrifuged at
12710,000 rpm for 10 min. Supernatant was transferred to new
128Eppendorf tubes, and 100 μl chloroformwas added. Using the
129chloroformed precipitation, a high grade of purity was
130reached; a high percentage of the presented lipids could be
131removed, which resulted in a good degree of ionization. The
132mixture was gently shaken for several seconds and then im-
133mersed into an ultrasonic water bath for precipitation 3 min
134(Wang et al. 2012; Zhang and Lee 2012). Phase separation
135was performed by a centrifugation immediately at 4,000 rpm
136for 5 min. To get just the precipitated proteins, both the
137organic and the aqueous phases were removed. Residual
138chloroform was removed using Speed Vac Concentrator
139(Concentrator Plus, Eppendorf). The effectiveness of the pro-
140tein precipitation was controlled byAutoflex II in both phases.
141It was used in linear mode, and 1 μl sample and 1 μl Sinapic
142acid (Bruker Daltonics, Bremen, Germany) matrix solution
143(the concentration was 10 mg/ml in acetonitrile/0.1 % TFA,
1441/2 v/v%) was mixed. The samples were lyophilized and
145stored at −80 °C until further process.
146Agilent-Automated Gel System
147Following the instructions of the manual of Agilent 2200
148TapeStation system (Agilent Technologies, Kromat KFT,
149Budapest, Hungary), P200 stain solution was prepared from
150the labeling dye and labeling buffer. Two microliters of buffer
151was mixed with 2 μl sample or ladder and heated for 7 min at
15275 °C. The mixture was denatured with the P200 reducing
153sample buffer and heated for 5 min at 75 °C. Two microliters
154of P200 marker was added to each sample or ladder, mixed,
155centrifuged, and pipetted into the 2200 TapeStation system.
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156 The experiments and semiquantitative data analysis were car-
157 ried out using the software of the 2200 TapeStation system.
158 One-Dimensional SDS Gel Electrophoresis
159 All chemicals and solvents for gel electrophoresis were pur-
160 chased from the BIO-RAD (Budapest, Hungary). The brain
161 samples from wild-type and PACAP-deficient mice were ho-
162 mogenized in 1 M Tris/HCl buffer, pH 8, containing 0.5 M
163 EDTA, 0.7 M beta-mercaptoethanol, and 10 % sodium dode-
164 cyl sulfate (SDS). After homogenization, the samples were
165 boiled for 5 min and clarified by centrifugation (8,000 rpm for
166 10 min). SDS-polyacrylamide gel electrophoresis (PAGE)
167 electrophoresis was carried out on 12 % polyacrylamide gel
168 according to Laemmli. ProSieveTM QadColorTM protein
169 marker, 4.6–300 kDa, was used for estimation of the molec-
170 ular weight. Gels were stained with Coomassie Brilliant Blue
171 R-250 and destined with a solution containing 5 % (v/v) acetic
172 acid and 16.5 % (v/v) methanol. The gels were analyzed by
173 Quantity One, BIO-RAD software.
174 The bands of interest were excised from the gel with a razor
175 blade, placed in Eppendorf tubes, and destained by washing
176 three times for 10 min in 200 μL of 50 % (v/v) acetonitrile
177 solution containing 50 mM NH4HCO3 (pH: 8.3). Proteins
178 were then reduced by 50 μL of 10 mM dithiothreitol in
179 50 mM NH4HCO3 for 1 h at 55 °C and alkylated in 50 μL
180 of 55 mM iodoacetamide in 50 mM NH4HCO3 solution. The
181 gel pieces were dehydrated at room temperature by a Speed
182 Vac Concentrator and covered with 10 μL of modified trypsin
183 (sequencing grade, Promega, Madison, WI, USA), 5 ng/μL in
184 NH4HCO3 buffer (50 mM, pH: 8.3), and left at 37 °C over-
185 night. The excised bands were crushed, and peptides were
186 extracted by frequent vortexing with 50 μL aqueous solution
187 of acetonitrile and formic acid (44/50/6 v/v/v). The samples
188 were lyophilized and stored at −80 °C until further process.
189 Two-Dimensional SDS Gel Electrophoresis
190 The samples were homogenized in extraction buffer contain-
191 ing 8 M urea, 50 mM DTT, 4 % CHAPS, 0.2 % carrier
192 ampholytes, and 0.0002% bromophenol blue, which was also
193 used for IPG strip rehydration. The solubilized samples were
194 centrifuged at 10,000 rpm for 10 min to discard the insoluble
195 materials. Isoelectro focusing of the supernatant was per-
196 formed with rehydrated IPG strips (7 cm, pH 4–7 linear
197 gradient) using PROTEAN IEF System (BIO-RAD) with
198 the following parameters: 250 V for 20 min, 4,000 V for
199 1 h, and 4,000 V for 10,000 V forQ1 h. The current was
200 50 μA/strip. After the IEF, the strips were stored at −80 °C.
201 For the second dimension, the strips were incubated in
202 equilibration buffer (6 M urea, 2 % SDS, 0.05 M Tris/HCl
203 pH 8.8, and 20 % glycerol in ultrapure water) containing 2 %
204 DTT for 10 min, and, after, in the same buffer containing
2052.5 % iodoacetamide for 10 min. The strips were washed in
206SDS running buffer, placed on top of 12 % SDS-PAGE
207according to Laemmli. The gels were scanned using
208PharosFXTM (BIO-RAD) Image scanner and were analyzed
209using BIO-RAD’s PDQuestTM 2-D analysis software. All
210samples were analyzed in triplicate. Gels were stained, and
211then proteins of interest were digested by the same method as
212described above.
213MALDI TOF/TOF Mass Spectrometry-Based Identification
214After SDS-PAGE, the peptide solutions were lyophilized and
215redissolved in 0.1 % trifluoroacetic acid (TFA). The aqueous
216solutions of the lyophilized protein digests were enriched on a
217Protein Anchor chip target plate (MTPAnchorChip™ 384 T F,
218Bruker Daltonics, Bremen, Germany) by using of 1 μL of
219sample solution; after that, 1 μl diluted matrix solution (the
220concentration was 0.7 mg/ml), prepared freshly before each
221measurement by dissolving α-cyano-4-hydroxycinnamic acid
222(CHCA) in acetonitrile/0.1 % TFA (1/2, v/v) was added. An
223Autoflex Speed TOF/TOF (Bruker Daltonics) mass spectrom-
224eter operated in reflector mode for peptide mass fingerprinting
225(PMF) or LIFT mode for laser-induced decay (LID), and
226collision-induced decay (CID) was used. The FlexControl
2273.4 software was used to control the instrument. The acceler-
228ating voltage was set to 20.00 kV. The instrument uses a 1 kHz
229Smart beam II solid-state Nd:YAG UV laser (Lasertechnik
230Berlin GmbH., Berlin, Germany). External calibration was
231performed in each case using Bruker Peptide Calibration
232Standard (#206195 Peptide Calibration Standard, Bruker
233Daltonics). Peptide masses were acquired in the range of 500
234to 5,000m/z. Each spectrum was produced by accumulating
235data from 7,500 consecutive laser shots. Singly charged mon-
236oisotopic peptide masses were searched against Swiss-Prot and
237National Center for Biotechnology Information (NCBI) nr
238databases (last accessed 17 June 2013) by utilizing the
239MASCOT database search engine (version 2.3) (www.
240matrixscience.com, Matrix Science Ltd., London, UK) and
241Bruker ProteinScape server (Bruker Daltonics). Maximum
242two missed tryptic cleavage was considered, and the mass
243tolerance for monoisotopic peptide masses was set to a
244maximum of 150 ppm. The following possible modifications
245were included during data search: carbamidomethyl (C)-fixed,
246oxidation (M)-variable. Additionally, LID and CID fragmen-
247tation of three of the matched peptides were carried out with
248MALDI TOF/TOF to provide further evidence for the presence
249of the identified proteins.
250Results
251The peptide–protein profile of the different brain regions
252(frontal cortex, temporal lobe–diencephalon complex,
J Mol Neurosci
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253 mesencephalon, cerebellum, and the rest of the brainstem,
254 which consisted of the pons and the medulla) of wild-type-
255 and PACAP-deficient mice was mapped on an Agilent 2200
256 TapeStation automated 1-D gel system (Fig. 1). Separated gel
257 bands on the electropherogram show distribution of proteins
258 with different molecular weights in orientation and intensity
259 similar to detected peaks. Frontal cortex (a1 and a2 in Fig. 1)
260 and the rest of the brainstem (pons and medulla) (b1 and b2 in
261 Fig. 1) regions of wild-type and PACAP-knockout mice did
262 not show marked differences in protein composition. In con-
263 trast, significant differences were found in the mesencephalon
264 (c1 and c2 in Fig. 1) and temporal lobe–diencephalon com-
265 plex regions (d1 and d2 in Fig. 1) using Agilent 2200
266TapeStation system. Based on the electropherograms, differ-
267ent data from wild-type (a1 and b1 in Fig. 2) and PACAP-
268knockout mice (a2 and b2 in Fig. 2) were summarized in
269parallel. Figure 2(a2) shows several proteins (such as 50.8,
27055.5, 61.1, 80.0, and 176.5 kDa) decreased in mesencephalon
271samples of PACAP-knockout (KO) mice. In contrast,
27212.9 kDa protein concentrations increased in the same sam-
273ples. Furthermore, Fig. 2(b2) indicates that 14.9, 35.8, and
27452.8 kDa proteins markedly decreased in PACAP-knockout
275temporal lobe–diencephalon complex region in contrast to
276wild types in Fig. 2(b1).
277The main advantages of Agilent 2200 TapeStation system
278are the simple sample preparation and the capability of quick
Fig. 1 Protein map Q4ping of wild-type (1) and PACAP-knockout (2) mice
brains were examined by Agilent 2200 TapeStation in the following
regions: A frontal cortex, B rest of the brainstem (pons and medulla), C
mesencephalon, and D temporal lobe–diencephalon complex. The green
and the brown colors indicate the original P200 molecular weight markers
and the blue bands represent the different proteins from samples. Light
blue peaks are representing the relative intensities of different proteins
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279 measurements of a large number of samples, but its disadvan-
280 tage is its limited resolution. Based on this, we were able to
281 screen the different brain areas in a parallel fashion, but we
282 could not reach a resolution that is high enough. Therefore,
283 regions showing differences at first screening were further
284 analyzed using SDS-PAGE. The differences frommesenceph-
285 alon and temporal lobe–diencephalon complex, a commonly
286 used SDS-PAGE method was applied (Fig. 3). The SDS-
287 PAGE could separate the different protein bands with higher
288 resolution. Figure 3(a) represents the different protein contents
289 of mesencephalon in wild and PACAP-knockout samples.
290 The insert shows the gel region with the most marked differ-
291 ences between wild-type and knockout mice in the range of
292 ∼40–70 kDa. In this region, eight protein bands (∼39, 40, 45,
293 47, 50, 55, 60, and 70 kDa) with different intensity between
294 two samples were identified. Figure 3(b) represents the differ-
295 ent protein content of temporal lobe–diencephalon complex
296 region in wild and PACAP-knockout samples. The insert
297 shows the gel region with the most obvious differences
298between wild-type and knockout mice in the range of ∼35–
29955 kDa. In this range, six protein bands (∼35, 36, 37, 40, 47,
300and 50 kDa) with different intensity were identified. Since we
301could identify several proteins with MS analysis from the
302protein bands showing differences, 2-D electrophoresis was
303performed for more precise qualitative and quantitative anal-
304ysis. Differences on 2-D map of brain homogenates are pre-
305sented in Fig. 4a (mesencephalon) and b (temporal lobe–
306diencephalon complex). 2-D electrophoresis enabled the sep-
307aration of proteins over the entire pH 3–10 range and com-
308prised proteins between 4.6 and 300 kDa. The spot abundance
309values were highly comparable among all wild-type and
310knockout samples. The red arrows represent the main protein
311differences in wild-type animals, while the blue arrows show
312the same in knockout animals. Spots showing marked differ-
313ences between the two animal groups were excised and were
314further processed for MS analysis.
315We identified 22 proteins based on the sequences of the
316tryptic digests. From this protein pool, random representative
Fig. 2 Different parameters/data from Agilent 2200 TapeStation system;
the A1 and B1 panels were summarized between mesencephalon and
temporal lobe–diencephalon complex in wild-type samples. A2 and B2
panels show the measured results in the same regions in PACAP
knockout mice. The proteins with similar molecular weight are presented
in the same row of panel a2 and b2, while the proteins under limit of
detection are excluded and are presented with a dash
J Mol Neurosci
JrnlID 12031_ArtID 264_Proof# 1 - 21/02/2014
AUTHOR'S PROOF
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
317 mass spectra are shown for a protein with no difference
318 (Fig. 5a, glyceraldehyde-3-phosphate dehydrogenase), a pro-
319 tein being downregulated (Fig. 5b, glutathione S-transferase),
320 and another one upregulated (Fig. 5c, ATP synthase) in
321 PACAP-knockout samples. The identified 22 proteins are
322 summarized in Table 1, with the NCBI codes, functions,
323 Mascot score, and the sequence coverage. In PACAP-
324 knockout mice, 14 proteins out of the 22 identified ones
325 showed downregulation (peptidylprolyl isomerase A, gluta-
326 thione S-transferase, malate dehydrogenase 1, enolase 2, al-
327 dolase 1, aspartate aminotransferase, leucine-rich repeat con-
328 taining 9, phosphoglycerate mutase 1, pyruvate kinase,
329 aconitase-2, hemoglobin subunit beta-1, albumin 1, histone
330 (H1) domain, and secretin receptor), and in four proteins no
331 difference was found (cytochrome c oxidase, glyceraldehyde-
332 3-phosphate dehydrogenase, microphthalmia-associated
333transcription factor, and neurofascin). Four further proteins
334were identified that showed an upregulation in PACAP-
335knockout mice (ATP synthase, tubb2 protein–tubulin beta-2
336chain, spectrin alpha chain, and vinculin).
337Discussion
338Our study revealed several proteins that were up- or downreg-
339ulated in intact mice lacking endogenous PACAP. This is the
340first mass spectrometric analysis of PACAP-knockout mice
341using MS and Agilent 1-Dimension Automated 2200
342TapeStation system.
343Based on our current knowledge on mice lacking endoge-
344nous PACAP, it seems that there are no visible differences or
345only minor alterations are present in the brain morphology of
Fig. 3 SDS-PAGE of
mesencephalon (A) and temporal
lobe-diencephalon complex (B).
The inserts show the gel regions
with the biggest differences in
both cases. The bands were
analyzed with Quantity One
BIO-RAD software
Fig. 4 Proteomic profiling by
two-dimensional gel
electrophoresis. a
Mesencephalon, b temporal
lobe–diencephalon complex. The
results of wild-type and PACAP-
knockout samples are merged.
The red arrows represent the
wild-type protein spots, and the
blue arrows represent protein
spots from the knockout samples
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346 PACAP-KO mice at macroscopic or light microscopic levels
347 (Reglodi et al. 2012). However, when these mice are exposed
348 to harmful challenges, including hypoxia/ischemia, trauma,
349 and toxicity, PACAP-knockout mice respond with a signifi-
350 cantly increased lesion. This has been proven in models of
351 experimental autoimmune encephalomyelitis (Tan et al.
352 2009), brain ischemia (Ohtaki et al. 2006), retinal ischemia,
353 and retinal excitotoxicity (Endo et al. 2011; Szabadfi et al.
354 2012). Furthermore, mice lacking endogenous PACAP have
355 shown slower regeneration in spinal cord and peripheral nerve
356 injury (Armstrong et al. 2008; Tsuchikawa et al. 2012). These
357 results suggest that there must be biochemical alterations that
358 can be compensated under unchallenged conditions in the
359 absence of PACAP, but the compensatory mechanisms are
360 not sufficient to overcome injuries and to provide cellular
361 protection under challenged conditions. Our present results
362 may shed further light on the increased vulnerability of
363 PACAP-deficient mice against different challenges.
364One group of proteins, where marked differences were
365found, was proteins related to oxidative stress and antioxidant
366defense. These proteins were found to be downregulated in
367PACAP-knockout mice. Peptidylprolyl isomerase A(PPIase),
368for example, plays a key role in heat shock protein-induced
369stress response. Glutathione S-transferase is important in de-
370toxification and antioxidant defense. These results are in ac-
371cordance with earlier observations showing that PACAP-
372knockout mice have increased oxidative stress levels, with
373increased malonedialdehyde, decreased glutathione, and de-
374creased superoxide dismutase (Ferencz et al. 2010a, b).
375Furthermore, while no differences have been found in the
376antioxidant capacity and reactive oxygen species levels in
377the serum of knockout and wild-type mice at young ages,
378decreased antioxidant capacity accompanied by increased re-
379active oxygen species levels at older knockout mice has been
380found (Ohtaki et al. 2010). A recent study has investigated the
381PACAP-induced changes after cerebral ischemia in mice
Fig. 5 Matrix-assisted laser desorption ionization-time of flight
(MALDI-TOF) representative mass spectral profiles of the tryptic pep-
tides of different proteins: a glyceraldehyde-3-phosphate dehydrogenase,
b glutathione S-transferase, and c ATP synthase. The identification of the
resulted proteins was carried out by peptide mass fingerprinting workflow
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382 (Hori et al. 2012). The authors have found upregulation of
383 antioxidant defense molecules after PACAP administration. In
384 addition, an earlier study in PC12 cells found increased pro-
385 tective heat shock protein 27 levels while decreased neuro-
386 toxic heat shock protein expression after PACAP treatment
387 (Lebon et al. 2006). All these results, in accordance with our
388 present data, point to the importance of both endogenous and
389 exogenous PACAP in protection against oxidative stress.
390 Another group of proteins, where we found major differ-
391 ences between the two groups, was the group of glycosylation
392 enzymes. Malate dehydrogenase 1, enolase 2, aldolase 1,
393 phosphoglycerate mutase 1 (PGM), and pyruvate kinase
394 (PK) were downregulated, while ATP synthase was upregu-
395 lated. Similarly to the oxidative stress markers, the changes in
396 glycolytic enzymes in the present study are also in accordance
397 with the findings of Hori et al. (2012) showing that exogenous
398 PACAP influences the enzymes participating in glycosylation
399 are altered after PACAP treatment in favor of a positive energy
400 balance, supposedly providing protection in ischemic lesions.
401These results and our present observations suggest that en-
402dogenous PACAP is necessary for providing a favorable
403energy balance. In the lack of this regulatory mechanism, this
404energy balance is disturbed, making the organism more vul-
405nerable to noxious stimuli (hypoxia, ischemia, aging, toxins,
406and neurodegenerative conditions). These results are also in
407accordance with studies showing that stimulating this enzy-
408matic machinery provides neuroprotection in hypoxia (Zaman
409et al. 1999).
410Our results also show that PACAP-knockout mice might
411compensate this disturbed energy balance by increasing ATP
412synthase levels under intact or unstressed conditions. This is in
413accordance with the observations of Ohtaki et al. (2010)
414showing that young knockout mice do not have increased
415oxidative stress in contrast to aging mice. We found several
416other differences in protein composition, including structural
417proteins, the functional significance of which is under further
418investigation. It is well-known that results obtained from
419knockout mice have to be handled carefully and no direct
t1:1 Table 1 Identified proteins of wild-type and PACAP-knockout brain
samples. The first column shows the identification number (ID), the
second column represents the NCBI codes, the third column is the name
of identified protein, the fourth and fifth columns show the change of
amounts of proteins between wild-type and PACAP-knockout animals (+
the protein is present; − the protein is under limit of detection; +↓ the
protein is present, but its level is decreased; +↑ the protein is present, but
its level is increased). The sixth column shows the biological function of
the named proteins. The last three columns represent the molecular
weight (MW), Mascot Score and the sequence coverage (SC) in
percentage
t1:2 ID Accession Name Wild
type
Knockout Function MW
[kDa]
Mascot
Score
SC [%]
t1:3 1 gi|498752597 Hemoglobin subunit beta-1 + − Oxygen transport 15.8 111.0 88.4
t1:4 2 gi|6679439 Peptidylprolyl isomerase A + +↓ Catalytic enzyme, interaction
with HSPs
18.0 95.3 66.5
t1:5 3 gi|6754084 Glutathione S-transferase Mu 1 + +↓ Detoxification 26.0 91.1 63.3
t1:6 4 gi|407261468 Cytochrome c oxidase subunit 1 + + Mitochondrial respiratory chain 28.9 67.5 50.0
t1:7 5 gi|74224797 Malate dehydrogenase 1, NAD isoform + +↓ Catalytic enzyme 36.5 70.5 43.7
t1:8 6 gi|55153885 Glyceraldehyde-3-phosphate dehydrogenase + + Glycolytic enzyme 35.8 89.1 42.9
t1:9 7 gi|148677501 ATP synthase, isoform − + ATP synthesis 54.6 96.4 39.2
t1:10 8 gi|7305027 Enolase 2, gamma neuronal + +↓ Glycolytic enzyme 47.3 105.0 38.9
t1:11 9 gi|6671539 Aldolase 1, A isoform + +↓ Glycolytic enzyme 39.3 74.3 31.6
t1:12 10 gi|387106 Aspartate aminotransferase + +↓ Enzyme in amino acid metabolism 46.2 81.7 31.0
t1:13 11 gi|148704587 Leucine-rich repeat containing 9, isoform + +↓ Protein structure motif 81.7 63.4 25.1
t1:14 12 gi|42561824 MITF protein + + Transcription factor 38.6 83.7 33.8
t1:15 13 gi|114326546 Phosphoglycerate mutase 1 + +↓ Glycolytic enzyme 28.8 61.0 43.7
t1:16 14 gi|13097483 Tubb2 protein − + Structural protein 34.0 61.3 26.2
t1:17 15 gi|359807367 Pyruvate kinase, muscle isoform M1 + +↓ Glycolytic enzyme 57.9 135.0 36.2
t1:18 16 gi|26340966 Albumin 1 + +↓ Regulate the colloidal osmotic
pressure of blood
68.7 106.0 34.5
t1:19 17 gi|914317 Neurofascin + + Cell adhesion molecules 9.5 60.9 33.7
t1:20 18 gi|74189848 Spectrin alpha chain − + Erythrocyte structural protein 97.8 76.8 25.5
t1:21 19 gi|51313 Histone (H1) domain + +↓ Histone protein 20.8 65.7 64.9
t1:22 20 gi|74188189 Aconitase 2 + +↓ Catalytic enzyme 85.3 114.0 33.2
t1:23 21 gi|148669535 Vinculin, isoform − + Cytoskeletal protein 123.8 68.0 18.7
t1:24 22 gi|81882894 Secretin receptor + +↓ G-protein coupled receptor 50.9 62.1 15.0
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420 functional consequences can be drawn regarding the exact
421 endogenous actions of the molecule. The compensatory
422 mechanisms in case of PACAP-knockout mice are not fully
423 understood. Several attempts have been made to elucidate the
424 compensatory changes in the lack of PACAP. However, the
425 first studies found no differences in the monoaminergic neu-
426 rotransmitter systems (Ogawa et al. 2005). Subsequent exper-
427 iments hypothesized that there could be compensation by
428 vasoactive intestinal peptide (VIP), the peptide with the clos-
429 est structural homology to PACAP. In spite of this theoretical
430 possibility, no compensatory changes were found in the ex-
431 pression of VIP in the brain (Girard et al. 2006). Therefore, it
432 is still not known what mechanisms compensate the endoge-
433 nous lack of PACAP, and it is possible that indirect compen-
434 satory effects exist, like the here-described differences in the
435 proteins playing a role in the energy balance.
436 In summary, our present results open a novel direction to
437 investigate alterations in PACAP-deficient mice that may
438 explain their increased vulnerability to different harmful stim-
439 uli affecting the nervous system. Based on our present results,
440 it seems that endogenous PACAP affects energy homeostasis
441 and in lack of this neuropeptide, a disturbed energy balance
442 exists which is cannot be compensated in case of an environ-
443 mental challenge.
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